Form 4: DiaMedica Director Acquires 10,095 Shares via DSU Grant

DiaMedica Therapeutics Inc. Director James T. Parsons acquired 10,095 shares of common stock through a deferred stock unit grant in lieu of cash retainer fees.

Summary

• Director James T. Parsons acquired 10,095 shares of DiaMedica Therapeutics Inc. common stock.
• The acquisition occurred on January 2, 2026, at a price of $8.42 per share.
• These shares are issuable upon settlement of deferred stock units (DSUs) granted under the company's Amended and Restated 2019 Omnibus Incentive Plan.
• The DSUs were granted in lieu of $85,000 in cash retainer fees.
• The DSUs are scheduled to vest in four nearly equal installments on March 31, June 30, September 30, and December 31, 2026.
• Following this transaction, Mr. Parsons beneficially owns 97,949 shares directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The filing reports a routine equity compensation grant to a director, aligning their interests with shareholders and conserving company cash. This is generally viewed as a neutral to slightly positive event.

Positives

• Director Parsons' increased ownership aligns his interests with shareholders.
• The use of deferred stock units for compensation conserves cash for the company.

Future Outlook

The deferred stock units are scheduled to vest in four nearly equal installments throughout 2026, indicating future share issuance to the director.

Industry Context

This is a standard insider compensation disclosure. It reflects a common practice in the biotech/pharma industry (where DiaMedica operates) to use equity-based compensation to align director interests and conserve cash.

Comparison to Industry Standards

• The use of deferred stock units as part of director compensation is a common practice across many industries, including biotechnology, aligning director incentives with long-term shareholder value.
• Many companies, such as Biogen Inc. or Amgen Inc., utilize similar equity compensation plans for their non-employee directors.
• The specific value of $85,000 in lieu of cash retainer fees is within typical ranges for director compensation at companies of similar market capitalization, though specific comparisons would require detailed peer group analysis.

Corporate Governance

Related Party Transactions

• The transaction involves a director receiving deferred stock units as compensation, which is a standard related party transaction disclosed in accordance with SEC regulations.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders; potential for minor dilution upon vesting, but offset by cash conservation.
• Company: Conserves cash by utilizing equity for director compensation.

Next Steps

• Vesting of deferred stock units in four installments on March 31, June 30, September 30, and December 31, 2026.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction related to director compensation via deferred stock units. While it shows increased insider alignment, it does not present new fundamental information that would warrant a change in investment recommendation. It's a standard disclosure, not a catalyst for significant price movement.

Keywords

DiaMedica Therapeutics, DMAC, Form 4, Insider Trading, Stock Acquisition, Deferred Stock Units, Director Compensation, Equity Compensation, Rule 10b5-1